Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

NEXT STORY
Berkshire Grey to Present at the UBS Global Industrials and Transportation Virtual Conference on June 8, 2021
PREV STORY
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

NEXT STORY
Berkshire Grey to Present at the UBS Global Industrials and Transportation Virtual Conference on June 8, 2021
PREV STORY
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

author_avatar
NASDAQ Market News

Saniona publishes its interim report for the first quarter of 2021

author_avatar
NASDAQ Market News

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)

author_avatar
NASDAQ Market News